# Sanjay Popat

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sanjay-popat/

## Facts

| Field | Value |
| --- | --- |
| Citations | 30,973 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 62 |
| i10-index | 242 |
| Last Known Institution | Royal Marsden NHS Foundation Trust |
| OpenAlex ID | https://openalex.org/A5048231332 |
| ORCID iD | https://orcid.org/0000-0003-2087-4963 |
| Works | 833 |

## Researcher papers

Showing 12 of 15.

- [Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for/)
- [Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for-2/)
- [Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials](https://scholariq.org/papers/afatinib-versus-cisplatin-based-chemotherapy-for-egfr-mutation-positive-lung/)
- [Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry](https://scholariq.org/papers/immune-checkpoint-inhibitors-for-patients-with-advanced-lung-cancer-and/)
- [First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial](https://scholariq.org/papers/first-line-nivolumab-plus-ipilimumab-in-unresectable-malignant-pleural/)
- [Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-i-alk-i-positive-non-small-cell-lung-cancer/)
- [ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group](https://scholariq.org/papers/esmo-recommendations-on-the-use-of-circulating-tumour-dna-assays-for-patients/)
- [Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study](https://scholariq.org/papers/amivantamab-plus-chemotherapy-with-and-without-lazertinib-in-egfr-mutant/)
- [Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-alk-inhibitor-naive-advanced-alk-positive-nsclc/)
- [Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-advanced-alk-inhibitor-naive-alk-positive-non/)
- [Amivantamab plus Chemotherapy in NSCLC with <i>EGFR</i> Exon 20 Insertions](https://scholariq.org/papers/amivantamab-plus-chemotherapy-in-nsclc-with-i-egfr-i-exon-20-insertions/)
- [Targeting RET in Patients With <i>RET</i>-Rearranged Lung Cancers: Results From the Global, Multicenter <i>RET</i> Registry](https://scholariq.org/papers/targeting-ret-in-patients-with-i-ret-i-rearranged-lung-cancers-results-from-the/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Occupational and environmental lung diseases](https://scholariq.org/topics/occupational-and-environmental-lung-diseases/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [Royal Marsden NHS Foundation Trust](https://scholariq.org/institutions/royal-marsden-nhs-foundation-trust/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.